Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04943744 · ClinicalTrials.gov registry record · Early Phase 1
Gastrointestinal STRING Test With Oral Immunotherapy
A Early Phase 1 study, sponsored by Stanford University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04943744: Clinical Trial Early Phase 1 study, sponsored by Stanford University.
NCT04943744 is a Early Phase 1 study that was terminated before completion, run by Stanford University. The registered enrollment target is 13 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04943744, a Early Phase 1 study, was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of subjects treated with omalizumab-facilitated mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Primary Outcome
(defined as an EST score ≥ 2.9) in subjects receiving omalizumab-facilitated mOIT and/or mOIT with concurrent
Interventions
- BIOLOGICAL omalizumab
- DEVICE Entero-tracker
- BIOLOGICAL dupliumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2024-05-17 |
| Phase | Early Phase 1 |
Why NCT04943744 stopped before completion
NCT04943744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which omalizumab is the first listed.
NCT04943744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04943744 about?
NCT04943744 is a clinical study titled "Gastrointestinal STRING Test With Oral Immunotherapy". This STRING study will examine markers of esophageal inflammation using a minimally-invasive testing device, the esophageal string test (EST). The primary objective is to determine the effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic inflammation in the esophagus of ...
What is the current status of trial NCT04943744?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2021-05-17. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT04943744?
The interventions under investigation include: omalizumab (BIOLOGICAL), Entero-tracker (DEVICE), dupliumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04943744?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04943744's enrollment target sits among peer trials
13 1503rd of 2000 higher than 472 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI